Delay of tympanic membrane wound healing in rats with topical application of a tyrosine kinase inhibitor.
An animal model of chronic tympanic membrane (TM) perforation is needed for experiments on supporting wound healing of TM perforations. The epidermal growth factor receptor (EGFR) has been implicated in the regulation of wound healing. The object of this study was to investigate the efficacy of topical EGFR-inhibitor (erlotinib) to arrest wound healing of experimental TM perforation in rats. Bilateral instrumental myringotomies were performed in 13 male rats. A solution of erlotinib (10 mg/mL) was applied to one TM of each animal and vehicle only (control group) to the other side. The application procedure was repeated on both sides daily for 12 consecutive days. Thereafter, tympanic membranes were observed weekly for a total of 30 days. The mean healing period was found to be 12.1 days in the group with erlotinib and 6.4 days in the control group. The difference was significant. We observed differences in the histologic parameters between erlotinib group and control group. The inhibition of EGFR by topical application of erlotinib did delay the healing rate of myringotomies but seems not to be suitable to create a chronic TM perforation in rat.
Kaftan
Holger
H
Department of Otorhinolaryngology and Head and Neck Surgery, Ernst-Moritz-Arndt-University, Greifswald, Germany. h.kaftan@web.de
Reuther
Lars
L
Miehe
Bärbel
B
Hosemann
Werner
W
Herzog
Michael
M
D000287:Administration, Topical; D000818:Animals; D004195:Disease Models, Animal; D000069347:Erlotinib Hydrochloride; D008297:Male; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*; D011897:Random Allocation; D051381:Rats; D011917:Rats, Inbred Lew; D013997:Time Factors; D018058:Tympanic Membrane Perforation / Q000175:diagnosis / Q000188:drug therapy*; D014945:Wound Healing / Q000187:drug effects*
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride